Precision Oncology Trends
The latest news on precision oncology research trends.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.
The French cancer center will use OncoDNA's blood-based next-generation sequencing test, OncoFollow, in its ongoing SCANDARE study.
At the annual meeting, researchers demonstrated how the growing real-world database can be useful in answering myriad research questions.
The team will use NanoView's ExoView platform to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing therapy.
In a study presented at AACR, immunotherapy responses across 20 cancer types were consistently higher for tumors with TMB of at least 16 somatic mutations per megabase.
The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.
Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.